Consolidation With Autologous Hematopoietic Cell Transplant In First Remission Improves Overall Survival In Younger Patients With Mantle Cell Lymphoma In The Rituximab Era

Introduction : Mantle cell lymphoma (MCL) is a CD5+ B-cell lymphoma characterized by cyclin D1 expression. The disease has heterogeneous clinical outcomes: in a subset of patients, it is indolent but many others have an aggressive course with poor outcome. Consolidative autologous hematopoietic cell transplant (HCT) in 1st remission is often employed for fit patients ≤65; however the benefit of this approach remains uncertain without prospective validation in the rituximab era. Herein we retrospectively assessed the impact of HCT consolidation following induction therapy on survival in a large multicenter cohort of transplant eligible patients aged ≤65. Methods : We retrospectively studied adults with newly diagnosed MCL, aged ≤65, transplant eligible at diagnosis, and treated with induction chemotherapy from 2000-2015. Eligibility for transplant was determined by the institutional chart reviewer. 22 US and Canadian academic medical centers contributed. Information on prognostic markers, treatment, response to induction, and survival was collected. The primary objective was to assess for an overall survival (OS) benefit of HCT consolidation in first remission. A landmark survival analysis was restricted to patients surviving u003e6 months who achieved ≥partial response (PR) after induction, with OS and progression-free survival (PFS) defined as time from diagnosis to event (death or relapse). Cox multivariate regressions were performed to evaluate the effect of HCT consolidation on OS and PFS after adjusting for confounders (age, sex, MIPI, stage, induction regimen, blastoid/pleomorphic phenotype, response to induction (complete response (CR) vs. PR), and maintenance therapy. Due to the differential times of HCT, this was included in the model as a time-varying covariate. Ki67 was excluded from regression models as it was available in Results : Data was collected for 1113 patients, and 921 patients met inclusion criteria. HCT was performed in 595 patients (64%). The two most common reasons for not performing HCT were physician (46%) or patient preference (23%). Three centers, who contributed a combined 135 patients, performed HCT in st remission was associated with improved PFS (p Conclusion : In this large cohort of younger transplant eligible patients with MCL, HCT consolidation in first remission was associated with significantly improved OS and PFS after adjusting for prognostic factors and differences in initial treatment. Within the limitations of retrospective analysis and inherent selection bias, our findings support the benefit of HCT consolidation following induction therapy for fit patients ≤65 in the rituximab era. Disclosures Barta: Janssen: Membership on an entity9s Board of Directors or advisory committees; Seattle Genetics: Research Funding; Merck: Research Funding; Celgene: Membership on an entity9s Board of Directors or advisory committees, Research Funding; Takeda: Research Funding. Villa: Roche: Consultancy, Honoraria, Other: Travel, Research Funding; Lundbeck: Consultancy, Honoraria, Other: Travel; Seattle Genetics: Consultancy, Honoraria; Celgene: Consultancy, Honoraria; Amgen: Consultancy, Honoraria; Janssen: Honoraria; Abbvie: Other: Travel. Gerrie: Roche: Research Funding; Seattle Genetics: Honoraria, Membership on an entity9s Board of Directors or advisory committees; Lundbeck: Honoraria; Janssen: Membership on an entity9s Board of Directors or advisory committees. Fenske: Celgene: Consultancy; Sanofi: Consultancy; Pharmacyclics: Consultancy. Maddocks: Merck: Research Funding; Pharmacylics: Research Funding; BMS: Research Funding; Novartis: Research Funding. Lansigan: Spectrum Pharmaceuticals: Consultancy, Research Funding; Seattle Genetics: Consultancy. Reddy: Abbvie: Consultancy; BMS: Consultancy; Celgene: Consultancy; Gilead: Speakers Bureau. Landsburg: Curis: Consultancy, Research Funding; Takeda: Research Funding. Karmali: Celgene: Speakers Bureau. Kaplan: Takeda: Research Funding; Millennium: Research Funding; Seattle Genetics: Research Funding; Janssen: Research Funding. Caimi: Celgene: Speakers Bureau; Abbvie: Equity Ownership; Seattle Genetics: Equity Ownership; Incyte: Equity Ownership. Cohen: Takada: Research Funding; Bristol Myers Squibb: Research Funding; Abbvie: Consultancy, Membership on an entity9s Board of Directors or advisory committees; Janssen: Consultancy, Membership on an entity9s Board of Directors or advisory committees; Genentech: Consultancy, Membership on an entity9s Board of Directors or advisory committees; Bioinvent: Consultancy, Membership on an entity9s Board of Directors or advisory committees; Novartis: Consultancy, Membership on an entity9s Board of Directors or advisory committees, Research Funding; LAM Therapeutics, Inc: Research Funding; Infinity: Consultancy, Membership on an entity9s Board of Directors or advisory committees. Calzada: Seattle Genetics: Research Funding. Handorf: Pfizer: Research Funding. Bachanova: Seattle-Genetics: Consultancy, Membership on an entity9s Board of Directors or advisory committees; Juno: Membership on an entity9s Board of Directors or advisory committees; Oxis: Membership on an entity9s Board of Directors or advisory committees, Research Funding; Zymogen: Consultancy, Membership on an entity9s Board of Directors or advisory committees; Novartis Pharmaceuticals Corporation: Membership on an entity9s Board of Directors or advisory committees, Research Funding.